|

Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain Injury & Addiction (WESA)

ByPsychedelic Spotlight



Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain Injury & Addiction (WESA)

Dr. Nazeer is the Founder and President of APS Ketamine/Advanced Psychiatric Solutions, which
was recently acquired by Wesana Health (OTC: WSNAF, CSE: WESA), where he now assumes the role of Chief Medical Officer.

Dr. Nazeer is nationally known as a spokesperson in the areas of ketamine therapy, addiction medicine, pharmacogenomics, and psychiatry. Currently, he is running clinical research on the Relation of IV Ketamine to Neurocognitive Performance.
Dr. Nazeer is also providing medical oversight to the growth plan of Wesana Clinics.
Wasana is a company focused primarily on treating Traumatic Brain Injury (TBI) with Psychedelics. To start, they are testing psilocybin to treat TBI, though they have also recently partnered with MAPS to use MDMA.
Wesana is a company run by Daniel Carcillo, a Stanley Cup winning NHL player, and is partially funded by Mike Tyson.

In this preview with Psychedelic Spotlight, Dr Nazeer and Matthew of Psychedelic Spotlight discuss the shifting perception of psychedelics as medicines. Dr Nazeer actually opened the first Ketamine Clinic in Chicago 5 years ago. At the time everyone thought he was crazy. Now they recognize him as a trailblazer.
Nazeer claims that we are at “the turning point” for psychedelic medicines, and thinks we are 5 years away from these treatments becoming mainstream.

acquisition of Wesana
Can psychedelics treat mental health issues?
Can Psilocybin treat TBI?

These are the questions Dr. Nazeer and Wesana Health aim to answer.

#WesanaHealth #Psychedelics #addiction

source

Similar Posts

  • Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!

    Listen, Videos

    Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!!
    The trial will use Comp 360, the company’s synthetic, proprietary version of psilocybin, in conjunction with therapy. This is Compass’ second major trial using Comp 360. They also are using it to treat Treatment Resistant Depression.

    On October 3rd, 2021, Compass Pathways (Nasdaq: CMPS) announced the launch of a brand new psychedelic therapy clinical trial, using Psilocybin, the active ingredient in magic mushrooms, to treat PTSD.
    The Phase 2 clinical trial will use Comp 360, Compass Pathways’ proprietary, synthetic, cristalline Psilocybin. It will be paired with talk psychotherapy in 20 adults who suffered trauma as an adult, resulting in PTSD.
    While using psychedelics for mental health may seem controversial, when it comes to the science, psychedelics like psilocybin and MDMA, when paired with therapy have been shown to work.
    For example, recently MAPS completed a Phase III clinical trial using MDMA therapy to treat PTSD, which showed 67% of people improving so much they no longer qualified to be diagnosed as having PTSD (cured?). Another 21% of people improved significantly.

    This Compass Pathways trial is exciting, because once it is complete, we will be able to compare the results of their psilocybin trial to MAPS’ MDMA trial, to start to have an understanding of which psychedelic compound works better for treating PTSD.
    This news comes as we are waiting for the results of Compass Pathways’ Phase 2b Clinical Trial, testing treating Treatment-Resistant Depression with Comp 360, to be released before the end of the year.
    The results of the trial will be significant, as it will be the largest ever clinical trial studying psychedelics, with 216 patients. It will also be the most advanced clinical trial studying psilocybin, being in phase 2b.
    In sum, these are very exciting times to be watching Compass Pathways. Controversies surrounding their patents aside, Compass is one of the companies pushing the frontiers of psychedelic medicines, which is very exciting to watch.

    Do you think psilocybin assisted therapy could treat PTSD? Let us know in the comments.

    Enjoy the episode!
    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com
    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #Psychedelics #CMPS

  • The Spotlight Round Up Video, March 31st

    Listen, Psychedelic Spotlight Videos

    As we continue to strive to be the leading source for news and unique perspective within the emerging sector of medicinal psychedelics, we are excited to debut the Spotlight Roundup! This video series, produced in collaboration with Elk’s Pride Pictures, provides a concise and informative roundup related to some of the most important news developments happening within this rapidly expanding industry. From the latest IPO’s, to new clinical trials, the Spotlight Roundup covers everything you need to know!

  • Interview With Dr. Steven Mandel

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast, we have the distinct privilege of speaking with one of the foremost experts in ketamine-assisted therapy, Dr. Steven L. Mandel, Founder and President of Ketamine Clinics Los Angeles.

  • MindMed Raises $19.5 Million // What Does This Mean for MMEDF/MMED? [Plus Upcoming Market CRASH?]

    Listen, Videos

    Hey guys! Today’s episode is more of a fast rant on the recent press release about MindMed raising ANOTHER $19.5M from Canaccord Genuity Corp, on a deal that is set to close tomorrow, March 9th.
    Here, I’m discussing:
    1. The number MindMed shares being sold and their respective price;
    2.Why is MindMed doing this?
    3. Potential short term and long term effects on MMED’s stock price
    4. Nasdaq uplisting?
    5. Market crash thoughts

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #MMEDNews